6UJB image
Entry Detail
PDB ID:
6UJB
EMDB ID:
Title:
Integrin alpha-v beta-8 in complex with the Fabs C6D4 and 11D12v2
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2019-10-02
Release Date:
2020-02-05
Method Details:
Experimental Method:
Resolution:
3.51 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Integrin alpha-V
Chain IDs:A
Chain Length:1018
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Integrin beta-8
Chain IDs:B
Chain Length:727
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:C6D4 heavy chain Fab
Chain IDs:C (auth: E)
Chain Length:212
Number of Molecules:1
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Description:C6D4 light chain Fab
Chain IDs:D (auth: F)
Chain Length:219
Number of Molecules:1
Biological Source:Mus musculus
Primary Citation
Cryo-EM Reveals Integrin-Mediated TGF-beta Activation without Release from Latent TGF-beta.
Cell 180 490 ? (2020)
PMID: 31955848 DOI: 10.1016/j.cell.2019.12.030

Abstact

Integrin αvβ8 binds with exquisite specificity to latent transforming growth factor-β (L-TGF-β). This binding is essential for activating L-TGF-β presented by a variety of cell types. Inhibiting αvβ8-mediated TGF-β activation blocks immunosuppressive regulatory T cell differentiation, which is a potential therapeutic strategy in cancer. Using cryo-electron microscopy, structure-guided mutagenesis, and cell-based assays, we reveal the binding interactions between the entire αvβ8 ectodomain and its intact natural ligand, L-TGF-β, as well as two different inhibitory antibody fragments to understand the structural underpinnings of αvβ8 binding specificity and TGF-β activation. Our studies reveal a mechanism of TGF-β activation where mature TGF-β signals within the confines of L-TGF-β and the release and diffusion of TGF-β are not required. The structural details of this mechanism provide a rational basis for therapeutic strategies to inhibit αvβ8-mediated L-TGF-β activation.

Legend

Protein

Chemical

Disease

Primary Citation of related structures